Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
The firm said its test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost, and labor.
The drugstore will sell Pixel by Labcorp kits in up to 6,000 stores, with the goal of providing a testing option at stores that don't currently have on-site testing.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.
The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
